Joint Supplement Tied to Higher Dementia Progression Risk

Millions of older adults take glucosamine every day for joint pain. New research suggests it might be doing more harm than good — for their brains.A large study published in Nature Metabolism looked at electronic health records from over 24,000 patients with Alzheimer's and related dementias, plus nearly 42,000 with mild cognitive impairment. About 8% were taking glucosamine.The finding: glucosamine use was tied to a 25% higher chance of progressing from mild cognitive impairment to full dementia within 5 years. In patients already diagnosed with dementia, it was linked to a 25% higher risk of death within 10 years.So what's going on? Researchers point to a process called glycosylation — think of it as the cell's labeling and shipping system, tagging proteins so they fold and function correctly. In Alzheimer's brains, this system may be running into overdrive.In postmortem brain tissue, scientists found this excess sugar-tagging increased right along with disease severity. Then, in mouse models, they saw it firsthand: dialing down glycosylation improved cognition, while giving mice glucosamine made things worse.Here's the catch — this is observational data. It shows an association, not proof that glucosamine directly causes decline. But experts say the signal is hard to ignore, especially because glucosamine has never shown dramatic benefits for the conditions it's typically used for.So where does this evidence leave clinical practice? Experts say this isn't a call to panic or to stop supplements overnight. But it is a reason to start the conversation — especially with patients who have mild cognitive impairment or dementia. Experts are now calling for large clinical trials to nail down whether glucosamine truly accelerates cognitive decline.Bottom line: the evidence isn't conclusive, but the research suggests it’s notable enough that glucosamine may be worth a second look in your at-risk patients.This video is based on a recent Medscape article titled " Popular Joint Supplement Tied to Faster AD Progression" and was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.